Novavax

Overview

This is a research study of an investigational vaccine made by Novavax, Inc. called “SARS-CoV-2 rS with Matrix-M1™ Adjuvant”. The study is a multicenter, global study with countries selected based on the expected COVID-19 epidemiology and healthcare system characteristics. The objectives are to determine whether the vaccine prevents COVID-19 disease, to see if the study vaccine continues to be safe for people to use, and whether it may cause side effects, and to see what different types of immune responses are stimulated by the study vaccine. About 30,000 adults (≥ 18 years) at roughly 125 study sites will participate in the study for about 2 years.

Last updated December 20, 2021